Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 21

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  multiple myeloma
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Multiple myeloma - interdiscipline diagnostic problem

100%
Gorska M., Jawniak D., Hus I., Horobowska J.
Polish Journal of Environmental Studies
|
2004
|
tom 13
|
nr Suppl.2, Part 1
Multiple myeloma (MM) is an uncurable plasma cell malignancy, with incidence approximately 4 per 100 000 population and rich symptomatology causing often significant diagnostic problems. In 1992-2004 in Haematology Department of Medical University in Lublin MM was diagnosed in 197 patients (110 woman and 87 men, mean age 61± 11.2 years). The most common monoclonal protein type of was IgG, detected in 133 patients. At the time of initial diagnosis in 138 patients bone pain was a main complain, in 10,2% of these patients it was caused by pathological fractures. In 20 patients (10.2%) clinical course was indolent, and disease was diagnosed accidentally. In the other patients first clinical manifestation were unspecific symptoms, such as: general weeknes (15/197 patients), paraparesis (9/197), acute renal failure (8/197), prolonged infections (8/197) bone of soft tissue tumours (7/197). Taking into account unspecific clinical picture preliminary diagnostics should focus on characteristic for MM laboratory features, i.e.: highly accelerated erythrocyte sedimentation reaction resulted from hyper- and para-proteinaemia; proteinuria; osteolytic lesions in bone radiograms. Lack of appropriate diagnostic strategy prolongs time to therapy commencement to 5.3±4.7 months, in some cases even to 24 months. On the level of basic health care total protein serum level and bone radiograms are adequate diagnostic investigation to establish preliminary diagnosis of MM. In our study increase of total protein serum level and characteristic changes in bone radiograms were found in 96% of patients.
2

Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients

100%
Zdzisinska B., Walter-Croneck A., Dmoszynska A., Kandefer-Szerszen M.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
tom 54
|
nr 4
3

The use of the Congo red-related dye DBACR to recognize the heavy chain-derived abnormality of myeloma immunoglobulins

100%
Spolnik P., Konieczny L., Piekarska B., Rybarska J., Stopa B., Zemanek G., Drozd A., Krol M., Roterman I., Wolska-Smolen T., Skotnicki A. B.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
tom 54
|
nr 3
4

Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells

84%
Zdzisinska B., Bojarska-Junak A., Walter-Croneck A., Kandefer-Szerszen M.
Archivum Immunologiae et Therapiae Experimentalis
|
2010
|
tom 58
|
nr 2
153-163
5
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma

84%
Szudy-Szczyrek A., Legiec W., Manko J., Gmyz K., Szczyrek M., Hus M.
Health Problems of Civilization
|
2015
|
tom 09
|
nr 2
Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.
6

Plasma and plasma cell surface measurements of urokinase plasminogen activator system in multiple myeloma patients

84%
Dmoszynska A., Cioch M., Walter-Croneck A., Jawniak D., Hus I., Rolinski J.
Bulletin of the Veterinary Institute in Puławy. Supplement
|
2002
7

Abnormal cytokine production by bone marrow stomal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

84%
Zdzisinska B., Bojarska-Junak A., Dmoszynska A., Kandefer-Szerszen M.
Archivum Immunologiae et Therapiae Experimentalis
|
2008
|
tom 56
|
nr 3
8

Autologous peripheral blood stem and progenitor cells transplantation as a valid treatment approach in recurrent, refractory lymphoma

84%
Holowiecki J., Wojnar J., Markiewicz M., Waclawik A., Jagoda K., Kaminska H., Kachel L., Wojciechowska M., Kata D.
Archivum Immunologiae et Therapiae Experimentalis
|
1995
|
tom 43
|
nr 3-4
9

Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients

84%
Kraj M., Owczarska K., Sokolowska U., Centkowski P., Poglod R., Kruk B.
Archivum Immunologiae et Therapiae Experimentalis
|
2005
|
tom 53
|
nr 5
10

The levels of sMUC-1 in patients with multiple myeloma

67%
Lemancewicz D., Bolkun L., Porowska H., Galar M., Semeniuk J., Kloczko J., Dzieciol J.
Folia Histochemica et Cytobiologica
|
2011
|
tom 49
|
nr 4
11

Cancer immunoprevention: current status and future directions

67%
Keshavarz-Fathi M., Rezaei N.
Archivum Immunologiae et Therapiae Experimentalis
|
2021
|
tom 69
|
nr 1
12

Treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis

67%
Wach M., Cioch M., Hus M., Jawniak D., Legiec W., Malek M., Manko J., Walter-Croneck A., Wasik-Szczepanek E., Dmoszynska A.
Folia Histochemica et Cytobiologica
|
2011
|
tom 49
|
nr 2
13

Flow cytometric immunophenotypic characteristics of plasma cell leukemia

67%
Kraj M., Kopec-Szlezak J., Poglod R., Kruk B.
Folia Histochemica et Cytobiologica
|
2011
|
tom 49
|
nr 1
14

A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of muliple myeloma patients in response to RPMI8226 myeloma cells

67%
Zdzisinska B., Rolinski J., Piersiak T., Kandefer-Szerszen M.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 1
69-74
15

The application of CAR-T cells in haematological malignancies

67%
Skorka K., Ostapinska K., Malesa A., Giannopoulos K.
Archivum Immunologiae et Therapiae Experimentalis
|
2020
|
tom 68
|
nr 6
16

Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer: Part II

67%
Wilczynski J., Duechler M., Czyz M.
Archivum Immunologiae et Therapiae Experimentalis
|
2011
|
tom 59
|
nr 4
17

Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignances: induction under therapy with IL-2

67%
Kandefer-Szerszen M., Legiec W., Dmoszynska A., Rzeski W.
Archivum Immunologiae et Therapiae Experimentalis
|
1997
|
tom 45
|
nr 5-6
18

Modulating effect of interleukin 2 therapy on interferon production by blood leucocytes of patients with minimal residual hematological disease

67%
Kandefer-Szerszen M., Legiec W., Dmoszynska A., Szuster-Ciesielska A.
Archivum Immunologiae et Therapiae Experimentalis
|
1997
|
tom 45
|
nr 2-3
19

Interferon gamma as immunomodulator in a patient with multiple myeloma

67%
Kaminska T., Dmoszynska A., Cioch M., Hus I., Jawniak D., Szuster-Ciesielska A., Kandefer-Szerszen M.
Archivum Immunologiae et Therapiae Experimentalis
|
1999
|
tom 47
|
nr 2
20

Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine

67%
Czyzewski K., Zaborowska A., Styczynski J.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
tom 54
|
nr 5
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.